Reported 28 days ago
Goldman Sachs analyst Chris Shibutani highlights the importance of Pfizer's new R&D head, Dr. Mikael Dolsten, in the company's efforts to redefine its post-pandemic growth strategy. After outperforming Q3 expectations with a 23% revenue increase, Pfizer faces scrutiny from activist investors questioning its spending and acquisitions. Shibutani emphasizes that innovation will be key to navigating future success in the biopharma industry.
Source: YAHOO